Market Overview - The market experienced fluctuations with mixed performance among the three major indices, where the Shanghai Composite Index rose by 0.39%, the Shenzhen Component Index increased by 0.11%, while the ChiNext Index fell by 0.24% [1] Sector Performance - Sectors such as glass fiber, chemical pharmaceuticals, and biological products showed significant gains, while multi-financial, software development, and battery sectors faced declines [1] - Major capital inflows were observed in the chemical pharmaceuticals, electric power, and banking sectors [1] Innovation Drug Sector - The National Healthcare Security Administration and the National Health Commission issued measures to support the high-quality development of innovative drugs, emphasizing the use of medical insurance data for drug research and development [2] - According to Guojin Securities, the innovative drug sector is currently undervalued, with an increase in the number and quality of new drug approvals in China since the beginning of 2025 [2] Gold Market Outlook - U.S. President Trump criticized the Federal Reserve for not lowering interest rates, with expectations of a rate cut later this year and three cuts next year [3] - China Galaxy Securities predicts that COMEX gold prices may steadily break through $3,300 per ounce, with potential to reach $3,500 in extreme risk scenarios [3] Banking Sector Analysis - The People's Bank of China indicated a continuation of accommodative monetary policy, with expectations for further interest rate cuts and a potential reserve requirement ratio reduction [3] - Guosheng Securities highlighted the ongoing attractiveness of the banking sector, citing a dividend yield of 5.13% compared to a 10-year government bond yield of 1.66%, indicating a significant yield spread [4]

Market Overview - A-shares showed mixed performance with the Shanghai Composite Index up by 0.39%, Shenzhen Component Index up by 0.11%, and ChiNext Index down by 0.24% as of July 1, 2025 [1] - The total trading volume in the Shanghai and Shenzhen markets reached 1.466 trillion yuan [1] Innovation Drug Sector - The innovation drug sector led the market gains, with various ETFs such as the Innovation Drug ETF FuGuo (159748) rising by 5.88% and others like the Hong Kong Innovation Drug ETF (159570) increasing by over 4% [2] - The National Healthcare Security Administration and the National Health Commission issued measures to support the high-quality development of innovative drugs, focusing on R&D, access, hospital use, and multi-payment systems [2] - The inclusion of commercial health insurance innovative drug catalogs in the adjustment plan aims to enhance the multi-tiered medical security system [2] - Zhongyin Securities noted that the innovation drug sector has long-term investment value, driven by the "18A" policy and the influx of medical companies listing in Hong Kong [2] Financial Technology Sector - The financial technology sector experienced a pullback, with the release of the "Hong Kong Digital Asset Development Policy Declaration 2.0" aiming to position Hong Kong as a global innovation center for digital assets [3] - The policy includes regularizing the issuance of tokenized government bonds and promoting broader asset and financial tool tokenization [3] - The domestic financial technology market is projected to grow at a compound annual growth rate of approximately 13.3% due to various development plans [3] ETF Market Activity - The Hong Kong-related ETFs showed high trading activity, with the Hong Kong Stock Connect 50 ETF (159712) having a turnover rate of 1067.75% [4][5] - The top traded ETF by volume was the Huabao Tianyi ETF (511990), with a transaction amount of 14.25 billion yuan [4] - Four new ETFs are set to launch, including the A500 Enhanced ETF and the Huazhong A500 Enhanced ETF, focusing on a balanced industry distribution and targeting new productivity sectors [6] Sector-Specific ETFs - The Hong Kong Stock Connect Consumer 50 ETF focuses on consumer upgrade leaders, targeting sectors like trendy toys and domestic gold [6] - The Hong Kong Stock Connect China Technology 30 ETF emphasizes AI and technology sectors, with over 70% weight in semiconductor, hardware, and software services [7]

Group 1 - The innovative drug ETF from Fuqian (159748) has risen over 4%, reaching a new 5-day high [1] - The premium rate stands at 4.04%, with a trading volume of 12.7387 million yuan, which is an increase of 81.32% compared to the same time yesterday [1] - The trading volume has decreased by 34 million units over the past month [1] Group 2 - The strategy suggests buying index ETFs to capitalize on market rebounds, focusing on leading companies in the sector [1]